ABA Autism denied as not FDA-approved for this use by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for aba autism are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UHC Issues a "Not FDA-Approved" Denial for ABA

Applied Behavior Analysis (ABA) is a behavioral therapy, not a drug or device — it does not require FDA approval and has never been subject to FDA review. When UnitedHealthcare issues a "not FDA-approved" denial for ABA in the context of autism spectrum disorder (ASD), it almost always reflects a coding or administrative error: either the claim was submitted under a code that UHC's system reads as a pharmaceutical or device claim, or the denial language is a templated response that was misapplied to a behavioral health service. This type of denial is typically resolved through appeal with minimal clinical argument — the primary argument is definitional.

## What to Do First

Call UHC's member services line immediately with the denial letter in hand. Confirm how the claim was coded (CPT or HCPCS codes) and ask whether the denial was generated by an automated system. Request a peer-to-peer review between your treating BCBA or prescribing physician and UHC's clinical reviewer if automated denial is confirmed. Many "not FDA-approved" ABA denials resolve at this stage without a formal appeal.

## Federal Appeal Rights

If peer-to-peer resolution fails, you have full appeal rights. Under ACA Section 2719, once internal appeals are exhausted, you may request free external review by an Independent Review Organization. ERISA Section 503 provides equivalent rights for self-funded employer plans. The external-review window is typically around four months from final internal denial. Given that this denial type is likely an administrative error, internal resolution is the faster path.

## Documentation to Gather

• Denial letter: Retain the exact language, denial code, and date — essential for the formal record.
• Claim submission details: Confirm with your provider's billing department that the correct behavioral health procedure codes were submitted.
• ASD diagnosis: Current formal diagnosis from a licensed psychologist or developmental pediatrician.
• BCBA credentials and treatment plan: Confirms this is a licensed behavioral health service, not a pharmaceutical intervention.
• Prescriber letter: Brief letter from the treating physician clarifying that ABA is a behavioral therapy service, not a drug or device, and requires no FDA clearance.

## Appeal Structure

1. Lead with the definitional argument: ABA is a behavioral therapy, categorically not subject to FDA drug or device approval. 2. Confirm correct CPT/HCPCS coding and attach the corrected claim if there was a billing error. 3. Include the prescriber letter and current treatment plan. 4. If UHC persists, file for external review — an IRO will readily identify a misapplied standard. 5. Preserve the full timeline in writing throughout.